Search Results for 'abbott'
-
Patient Monitoring
Abbott Introduces World's First Glucose Biosensor Designed for Athletes
The firm is collaborating with Supersapiens in launch of the Libre Sense Glucose Sport Biosensor in Europe.PR Newswire 09.18.20
-
Diagnostics
Abbott Launches COVID-19 Antibody Blood Test
Abbott begins shipping April 16 and intends to distribute 4 million tests in April.PR Newswire 04.15.20
-
Bigfoot Biomedical Raises $45M, Led by Abbott
Funds to support breakthrough therapy for 6M living with insulin-requiring type 1 and type 2 diabetes.Bigfoot Biomedical 01.13.20
-
Cardiovascular | Diagnostics
Abbott’s Heart Attack Blood Test Cleared
Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests.PR Newswire 09.27.19
-
Abbott Gains CE Mark for Two Pediatric Heart Devices
Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart.Abbott Laboratories 09.17.19
-
Cardiovascular | Surgical
Abbott to Acquire Cephea Valve Technologies
Acquisition to further bolster Abbott's position in therapies for mitral valve disease, the most common type of heart valve ailment.Abbott Laboratories 01.16.19
-
Cardiovascular | Surgical
FDA Approves Abbott's Device to Close Holes in Premature Infants' Hearts
First and only minimally invasive, transcatheter treatment approved for premature babies with a patent ductus, a life-threatening opening in their heart.Abbott Laboratories 01.14.19
-
10. Abbott Laboratories
$10.1 Billion ($20.9B total) KEY EXECUTIVES: Miles D. White, Chairman and CEO Brian J. Blaser, Exec. VP, Diagnostics Products Robert B. Ford, Exec. VP, Medical Devices Michael T. Rousseau, President, Cardiovascular and Neuromodulation Br…07.26.17
-
Software & IT | Testing
The Curious Case of Abbott and Alere
As MPO readers are certainly aware, Abbott Laboratories has been quite active in the M&A department this year. Following the string of medtech industry consolidation efforts—which shows absolutely no signs of slowing—Abbott purchased…Sam Brusco, Associate Editor 10.12.16
